Cassava SciencesSAVA
SAVA
About: Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
Employees: 29
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
146% more capital invested
Capital invested by funds: $168M [Q2] → $412M (+$245M) [Q3]
89% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 19
56% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 32
8% more funds holding
Funds holding: 146 [Q2] → 158 (+12) [Q3]
1.0% more ownership
Funds ownership: 28.27% [Q2] → 29.28% (+1.0%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
54% less call options, than puts
Call options by funds: $109M | Put options by funds: $235M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$116
4,485%
upside
Avg. target
$116
4,485%
upside
High target
$116
4,485%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
HC Wainwright & Co. Vernon Bernardino 39% 1-year accuracy 23 / 59 met price target | 4,485%upside $116 | Neutral Downgraded | 26 Nov 2024 |
Financial journalist opinion
Based on 254 articles about SAVA published over the past 30 days
Neutral
PRNewsWire
1 hour ago
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cassava To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Cassava between February 7, 2024 and November 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Jan. 23, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the February 10, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Neutral
Accesswire
8 hours ago
Investors who lost money on Cassava Sciences, Inc.(SAVA) should contact Levi & Korsinsky about pending Class Action - SAVA
If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124567&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
8 hours ago
Investors who lost money on Cassava Sciences, Inc.(SAVA) should contact Levi & Korsinsky about pending Class Action - SAVA
NEW YORK, NY / ACCESS Newswire / January 23, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124567&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
9 hours ago
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Cassava Sciences, Inc. to Contact the Firm Today!
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
Neutral
Accesswire
9 hours ago
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Cassava Sciences, Inc. to Contact the Firm Today!
NEW YORK CITY, NY / ACCESS Newswire / January 23, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
Neutral
PRNewsWire
10 hours ago
The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
NEW YORK , Jan. 23, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Neutral
Accesswire
17 hours ago
Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join – Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / January 22, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124529&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
17 hours ago
CASSAVA SCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
NEW ORLEANS, Jan. 22, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Texas.
Neutral
Accesswire
19 hours ago
SAVA LAWSUIT ALERT: Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124513&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
19 hours ago
ROSEN, A LEADING NATIONAL FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline.
Charts implemented using Lightweight Charts™